Sponsor Pipeline

ArriVent BioPharma, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
5
Active Trials
3
Recruiting
2
Phase 3
7
Disease Areas
4
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-04 NCT07185997
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's…
Trial sites expanded: 78 -> 88 locations
2026-07-28 NCT07066657
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Enrollment increased: 405 -> 572 participants
2026-07-28 NCT07066657
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Trial arms changed: 1 -> 2
2026-07-28 NCT07066657
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
date change Primary completion moved earlier: 2029-05 -> 2028-03
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-08-10 NCT07755436 Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and… Phase 1 Recruiting
Active Trials by Phase
Phase 3
2
Phase 1
3
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07185997 Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's… Non-Small-Cell Lung Cancer Recruiting
NCT05607550 Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally… Metastatic Non-Small Cell Lung Cancer Active, Not Recruiting
Phase 1
NCT07755436 Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and… Ovarian Cancer Recruiting
NCT07066657 A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors Locally Advanced or Metastatic Solid Tumors Recruiting
NCT05364073 Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer… Non-Small Cell Lung Cancer (NSCLC) Active, Not Recruiting
Disease Areas
Get alerts when ArriVent BioPharma, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free